The 18-Month MDR-TB Regimen Has a Successor - Summary - MDSpire
Commentary & Perspectives

The 18-Month MDR-TB Regimen Has a Successor

Six months, all-oral, better tolerated—and the infrastructure to make it work.

Share

A fivefold increase in pretomanid prescriptions within NHS England, from 9 patients per month in early 2024 to 45 in early 2025, highlights the UK's shift towards shorter all-oral regimens for multidrug-resistant tuberculosis (MDR-TB). This review by clinicians and pharmacists from Imperial College and Leeds Teaching Hospitals discusses overcoming challenges such as unlicensed drugs and safety monitoring. Key factors include expert oversight, funding pathways, and tailored protocols to promote safe and equitable access, alongside reduced treatment burden and improved outcomes for vulnerable populations.

Original Source(s)

The 18-Month MDR-TB Regimen Has a Successor

  • by Kerri Miller

  • April 16, 2026

Related Content

Temple Lung Center: Advances in Lung Care and Research in 2025

Pulmonary care is evolving rapidly, from earlier detection strategies to new minimally invasive therapies and expanding access to clinical trials.

  • by

  • April 13, 2026

  • 1 min
Sex Does Not Modify Asthma Attack Predictors

Prior attacks predict risk more strongly in male patients, while type 2 biomarkers perform similarly across sexes

Flu Vaccination Linked to Lower Heart, Stroke Risk After Infection

A Danish registry study suggests prior influenza vaccination is associated with lower short-term cardiovascular risk following breakthrough infection.